Sodium Bicarbonate for the prevention of contrast induced nephropathy in patients suspected with acute pulmonary embolism undergoing CTPA

Sodium Bicarbonate for the prevention of contrast induced nephropathy in patients suspected with acute pulmonary embolism undergoing CTPA - The Nefros study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38375

Enrollment

140

Registered

2009-07-13

Start date

2009-11-16

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute renale failure following contrast contrastnephropathy

Interventions

* group 1: sodium bicarbonaat 1,4% (3 ml/kg bodyweight) 1 hour prior to administration of contrast media. * group 2: CT-PA without any hydration.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: eGFR

Exclusion criteria

Exclusion criteria: * age

Design outcomes

Primary

Measure	Time frame
* mean increase in serumcreatinine 2-4 days after CT-PA.	—

Secondary

Measure	Time frame
* Increase in serum creatinine > 25% or > 44 µmol/l 4 days (+ / - 1 day) after CTPA with contrast media. * Increase in serum creatinine > 25% or > 44 µmol/l 2 months after CTPA with contrast media or the need for dialysis. * Increase in C-cystatine and NGAL 3 days (+/- 1 day) after CT-PA. * Increase in NGAL 2 hours after CT-PA.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)